(1 - 21 von 23
)
Variant BA 2 : "On n'est pas du tout inquiet", dit le docteur ...
www.rtl.fr
— INVITÉ RTL - Le docteur Robert Sebbag, infectiologue à l'Hôpital de la Pitié-Salpêtrière à Paris, estime que ce sous-variant est ... › actu › debats-societe › variant-ba-2-on...
Robert Sebbag , de la Croix-Rouge, réagit à la mobilisation: «Bluffé...
www.liberation.fr
› robert-s...
Robert Sebbag | Les Echos
www.lesechos.fr
Robert Sebbag est nommé coordinateur de la communication pharmaceutique Europe de la Fédération européenne des associations de ...
Dr Robert Sebbag : "Les bénévoles ne veulent pas contaminer les ...fr.news.yahoo.com › dr-robert-sebbag-bénévoles-ne...
fr.news.yahoo.com
· Dr Robert Sebbag, médecin attaché au service des maladies infectieuses et tropicales de l'Hôpital de la Pitié Salpêtrière à Paris et ...
Dr Robert Sebbag: "Volunteers don't want to infect fragile people"...
www.tellerreport.com
Dr Robert Sebbag, doctor attached to the infectious and tropical diseases department of the Pitié Salpêtrière Hospital in Paris and administrator of Action...
Dr Robert Sebbag | EuropaWire.eu
news.europawire.eu
First shipment marks a critical step in improving access to treatment worldwide Paris, France, and South San Francisco, United States,
Dr Robert Sebbag | AfricaNewsAnalysiswww.africanewsanalysis.com › tag › dr-robert-sebbag
www.africanewsanalysis.com
· Sanofi (EURONEXT: SAN and NYSE: SNY) announced on World Malaria Day that 300 million treatments of anti-malarial ASAQ Winthrop® have been ...
Collins wins eminent Sanofi-Institut Pasteur Award
wyss.harvard.edu
Collins wins eminent Sanofi-Institut Pasteur Award on Wyss Institute | Wyss Core Faculty member James J. Collins At a ceremony yesterday in Paris, Wyss Core…
Launch of semi-synthetic artemisinin a milest | EurekAlert!
www.eurekalert.org
The best therapy today for malaria is a drug combination that includes a derivative of artemisinin, now solely available from plants grown in Asia and Africa....
Patents not the issue when it comes to access - BioPharmaDispatch
pharmadispatch.com
Patents are not the issue when it comes to access to medicines and vaccines in developing countries, according to Sanofi's Dr Robert Sebbag.
APMnews - PHILIPPE DOUSTE-BLAZY SE REND AU SRI LANKA
www.apmnews.com
Le ministre de la Santé, Philippe Douste-Blazy, a quitté Paris dans la nuit de dimanche à lundi à destination du Sri Lanka, durement touché par le tsunami qui...
Mérieux Foundation delegation visits partners and programs in...
www.fondation-merieux.org
In November 2018, Mr. Alain Mérieux, Dr. Robert Sebbag, a Mérieux Foundation Board member, and Prof. Hubert Endtz, director of Applied ...
Press Room - Press Releases
www.news.sanofi.us
... access to medicines in underserved communities worldwide,” said Dr. Robert Sebbag, Sanofi's Vice President for Access to Medicines.
Trimovax - szczepionka przeznaczona dla krajów Trzeciego Świata - RMF...
www.rmf24.pl
Trimovax - szczepionka przeznaczona dla krajów Trzeciego Świata - RMF24.pl - Francuska szczepionka Trimovax – według brytyjskich badań - znacznie zwiększa...
Launch of antimalarial drug a triumph for UC Berkeley, synthetic ...news.berkeley.edu › › launch-of-antima...
news.berkeley.edu
· Robert Sebbag, vice-president of Access to Medicines at Sanofi. “This is a pivotal milestone in the fight against malaria.” The “semi-synthetic” ...
sortiert nach Relevanz / Datum